Profile data is unavailable for this security.
About the company
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
- Revenue in USD (TTM)390.00k
- Net income in USD-26.96m
- Incorporated2015
- Employees9.00
- LocationIterum Therapeutics PLC3 Dublin Landings, North Wall QuayDUBLIN D01 C4E0IrelandIRL
- Phone+353 19038354
- Websitehttps://www.iterumtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 12.94m | 4.00 | -- | 4.17 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 13.30m | 11.00 | -- | 1.64 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 13.41m | 85.00 | -- | 2.86 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 13.59m | 6.00 | -- | 1.13 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 14.62m | 17.00 | -- | 5.69 | -- | 3.49 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 14.64m | 9.00 | -- | -- | -- | 37.55 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Curis Inc | 11.65m | -36.56m | 14.87m | 33.00 | -- | -- | -- | 1.28 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -37.50m | 15.18m | 20.00 | -- | 0.4296 | -- | -- | -7,200.04 | -7,200.04 | 0.00 | 4.93 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 15.34m | 7.00 | 0.068 | 3.01 | -- | 5.39 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.42m | 360.00 | -- | -- | -- | 0.0107 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 15.47m | 2.00 | -- | 1.90 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -11.74m | 15.85m | 5.00 | -- | 1.70 | -- | -- | -0.638 | -0.638 | 0.00 | 0.1472 | 0.00 | -- | -- | 0.00 | -158.62 | -117.05 | -230.00 | -201.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.14 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 16.24m | 3.00 | -- | 1.57 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 16.40m | 4.00 | -- | 0.433 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Iterum Therapeutics PLC's reporting currency: US Dollar USD
3.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Apollon Financial LLCas of 31 Dec 2025 | 630.25k | 1.19% |
| Jane Street Capital LLCas of 31 Dec 2025 | 289.41k | 0.55% |
| Alchemi Wealth LLCas of 31 Dec 2025 | 268.89k | 0.51% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 264.77k | 0.50% |
| CapFinancial Partners LLCas of 30 Sep 2025 | 111.60k | 0.21% |
| UBS Securities LLCas of 31 Dec 2025 | 111.32k | 0.21% |
| Gen-Wealth Partners, Inc.as of 31 Dec 2025 | 84.63k | 0.16% |
| Virtu Americas LLCas of 30 Sep 2025 | 47.13k | 0.09% |
| Krilogy Financial LLCas of 31 Dec 2025 | 40.00k | 0.08% |
| Ground Swell Capital LLCas of 31 Dec 2025 | 20.48k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
